Skip to main content
SpringerLink
Log in

Phase II study of amonafide in patients with recurrent glioma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Treatment of supratentorial tumors-astrocytomas, oligo-dendrogliomas and optic glioma. In: Kornblith PL, Walker MD, Cassady JR (eds) Neurologic Oncology. J.B. Lippincott Company, Philadelphia, 1987, pp 117–154

  2. Brana MF, Sanz AM, Castellano JM, Roldan CM, Roldan C: Synthesis and cytostatic activity of benz(de)isoquinolin-1,3-diones. Structure-activity relationships. Eur J Med Chem 16: 207–212, 1981

    Google Scholar 

  3. Amonafide. Annual report to the food and drug administration. The National Cancer Institute, Bethesda, MD (March), 1989

  4. Hsiang Y, Jiang J, Liu LF: Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 36: 371–376, 1989

    Google Scholar 

  5. Lu K, McLean MA, Vestal ML, Newman RA: Pharmacokinetics of amonafide in dogs. Cancer Chemother Pharmacol 21: 134–138, 1988

    Google Scholar 

  6. Kleihues P, Berger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathology 3: 255–268, 1993

    Google Scholar 

  7. Jennison C, Turnbull BW: Confidence interval for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics 25: 49–58, 1983

    Google Scholar 

  8. Perez RP, Hash SL, Ozols RF, Comis RL, O'Dwyer PJ: Phase II study of amonafide in advanced and recurrent sarcoma patients. Invest New Drug 10: 99–101, 1992

    Google Scholar 

  9. Gallion HH, Lie PY, Alberts DE, O'Toole RV, O'Sullivan J, Mills G, Smith HO, Hynes HE: Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 46: 230–232, 1992

    Google Scholar 

  10. Higano CS, Goodman P, Craig JB, Kish JA, Rivkin SE, Wolf M, Crawford ED: Phase II evaluation of amonafide in renal cell carcinoma: A Southwest Oncology Group study. Invest New Drugs 9: 362–363, 1991

    Google Scholar 

  11. Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B: Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 9: 353–356, 1991

    Google Scholar 

  12. Hanson KH, Crowley J, Salmon SE, Keppen M, Braun TJ, Bonnett JD: Evaluation of amonafide in refractory and relapsing multiple myeloma: A Southwest Oncology Group study. Anti-Cancer Drugs 2: 247–250, 1991

    Google Scholar 

  13. Malviya VK, Liu PY, Alberts DS, Surwit EA, Craig JB, Hannigan EV: Evaluation of amonafide in cervix cancer, Phase II: A SWOG study. Amer J Clin Oncol 15: 41–44, 1992

    Google Scholar 

  14. Evans WK, Eisenhauer EA, Cormier Y, Ayoub J, Wierzbicki R, Laberge F, Shepherd FA: Phase II study of amonafide: Results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8: 390–395, 1990

    Google Scholar 

  15. Gesme DH Jr, Jett JR, Schreffler DD, Su JQ, Mailliard JA, Foley JF, Krook JE, Maksymiuk AW, Hatfield AK, Ebbert LP, Pfeifle DM, Morton RF, Tschetter LK, Schaefer PL: A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer 71: 2723–2726, 1993

    Google Scholar 

  16. Berger MZ, Kris MG, Gralla RJ, Marks LD, Potanovich LM, Dimaggio JJ, Heelan RT: Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. Amer J Clin Oncol 14: 124–1226, 1991

    Google Scholar 

  17. O'Dwyer PJ, Paul AR, Hudes GR, Walczak J, Ozols RT, Comis RL: Phase II study of amonafide (nafidamide, NCS 308847) in advanced colorectal cancer. Invest New Drugs 9: 65–67, 1991

    Google Scholar 

  18. Poplin E, Fleming T, MacDonald JS, Eisenberg P, Fisher RI, Conrad ME: Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study. Invest New Drugs 11: 47–51, 1993

    Google Scholar 

  19. Scheithauer W, Dittrich C, Kornek G, Haider K, Linkesch W, Gisslinger H, Depisch D: Phase II study of amonafide in advanced breast cancer. Breast Cancer Res Treat 20: 63–67, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Luke's Hospitals CCOP, 58123, Fargo, ND, USA

    Ralph Levitt

  2. Mayo Clinic and Mayo Foundation, 55905, Rochester, MN, USA

    Jan C. Buckner, Terrence L. Cascino, Patrick A. Burch, Judith R. O'Fallon & Bernd W. Scheithauer

  3. Iowa Oncology Research Association CCOP, 50314, Des Moines, IA, USA

    Roscoe F. Morton & Mark W. Westberg

  4. Geisinger Clinical Oncology Program, 17822, Danville, PA, USA

    Richard M. Goldberg & James G. Gallagher

Authors
  1. Ralph Levitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan C. Buckner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terrence L. Cascino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick A. Burch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roscoe F. Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark W. Westberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard M. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James G. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Judith R. O'Fallon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bernd W. Scheithauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levitt, R., Buckner, J.C., Cascino, T.L. et al. Phase II study of amonafide in patients with recurrent glioma. J Neuro-Oncol 23, 87–93 (1995). https://doi.org/10.1007/BF01058464

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01058464

Key words

Search

Navigation